Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxofulleram
- Development stage
- Unknown
- Lead developer
- Soleo Communications
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Topical
01
Overview
Oxofulleram is a water-soluble fullerene (C60) derivative developed by Solenne BV for the topical treatment of inflammatory skin conditions, specifically papulopustular rosacea. As a fullerene-based compound, it functions primarily as a potent radical scavenger or antioxidant, neutralizing reactive oxygen species (ROS) that contribute to the chronic inflammation and vascular changes characteristic of rosacea. By reducing oxidative stress in the dermis, Oxofulleram aims to alleviate the inflammatory lesions (papules and pustules) associated with the condition. It has been evaluated in Phase 2 clinical trials in the Netherlands to determine its clinical applicability and safety profile in patients with moderate to severe rosacea.
- Other names
- fullerene C60 derivative
Beyond the preview
Go deeper on oxofulleram.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxofulleram.